Sun Pharmaceutical Industries Limited (SUNPHARMA) — Announcement

📢 Key Event
Sun Pharma outlines FY26 financials and strategic growth drivers in investor presentation

🔄 What Changed
27.1% EBITDA margin and 18.8% net margin for FY26

🔮 What's Next
Organon acquisition announced for 2026

💡 Investor Takeaway
Investors should note the strategic shift toward high-margin innovative medicines and global expansion through acquisitions.

Sun Pharmaceutical Industries Limited presented its FY26 investor outlook, highlighting Rs 582.2 Bn revenue, 27.1% EBITDA margin, and 18.8% net margin, with Innovative Medicines contributing 22% of sales and a 24% CAGR since FY18. The presentation underscores its global footprint across 100+ countries, 40 manufacturing sites, and strategic focus on dermatology, oncology, and complex generics, supported by 6.7% R&D investment and ESG commitments like 41% renewable energy use.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This